医学
冠状动脉疾病
支架
心肌梗塞
心脏病学
内科学
西罗莫司
靶病变
外科
血栓形成
药物洗脱支架
依维莫司
不利影响
再狭窄
经皮冠状动脉介入治疗
作者
Sebastian Kufner,Michael Joner,Anna Thannheimer,Petra Hoppmann,Tareq Ibrahim,Katharina Mayer,Salvatore Cassese,Karl‐Ludwig Laugwitz,Heribert Schunkert,Adnan Kastrati,Robert A. Byrne
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2019-01-14
卷期号:139 (3): 325-333
被引量:114
标识
DOI:10.1161/circulationaha.118.038065
摘要
New-generation drug-eluting stents offer the potential for enhanced late outcomes in comparison with early generation drug-eluting stents. However, assessment of extended long-term outcomes for these devices is lacking, especially regarding the comparison between new-generation drug-eluting stents with biodegradable or permanent polymers. The aim of this study is to compare the efficacy and safety of biodegradable polymer-based sirolimus-eluting stents (BP-SES; Yukon Choice PC) versus permanent polymer-based everolimus-eluting stents (PP-EES; Xience) versus early generation permanent polymer-based sirolimus-eluting stents (PP-SES; Cypher) at 10-year follow-up.Overall, 2603 patients were randomized to treatment with BP-SES (n=1299), PP-EES (n=652), or PP-SES (n=652). The primary end point of this analysis was major adverse cardiac event, the composite of death, myocardial infarction, or target lesion revascularization. The main secondary end point of interest was definite/probable stent thrombosis. Follow-up at 10 years was available in 83% of the study patients.The 10-year incidence of major adverse cardiac event (BP-SES 47.7% versus PP-EES 46.0% versus PP-SES 54.9%, P=0.003) and mortality (BP-SES 31.8% versus PP-EES 30.3% versus PP-SES 37.2%, P=0.02) was different among the groups. Definite/probable stent thrombosis was not significantly different among the groups (BP-SES 1.8% versus PP-EES 2.5% versus PP-SES 3.7%, P=0.09). Definite stent thrombosis was significantly different among the groups (BP-SES 1.1% versus PP-EES 0.8% versus PP-SES 2.4%, P=0.03). There were no significant differences between BP-SES and PP-EES.In this unique long-term outcome analysis, BP-SES and PP-EES showed comparable clinical outcomes out to 10 years. PP-SES had higher rates of major adverse cardiac events and definite stent thrombosis.URL: https://www.clinicaltrials.gov . Unique identifier: NCT00598676.
科研通智能强力驱动
Strongly Powered by AbleSci AI